Rein Therapeutics Inc.
RNTX
$1.27
$0.1412.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.00% | -1.88% | 22.07% | 100.76% | 89.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.60% | 42.84% | 83.16% | 132.31% | 47.93% |
| Operating Income | 4.60% | -42.84% | -83.16% | -132.31% | -47.93% |
| Income Before Tax | -140.65% | -247.70% | -309.53% | -125.97% | -44.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -134.53% | -239.15% | -299.71% | -125.97% | -44.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.53% | -239.15% | -299.71% | -125.97% | -44.28% |
| EBIT | 4.60% | -42.84% | -83.16% | -132.31% | -47.93% |
| EBITDA | 4.19% | -43.78% | -84.18% | -133.42% | -48.40% |
| EPS Basic | 17.09% | 10.41% | -2.30% | -9.30% | 15.65% |
| Normalized Basic EPS | 67.46% | 61.89% | 42.52% | -18.04% | 10.80% |
| EPS Diluted | 17.09% | 10.41% | -2.30% | -9.30% | 15.65% |
| Normalized Diluted EPS | 67.46% | 61.89% | 42.52% | -18.04% | 10.80% |
| Average Basic Shares Outstanding | 138.41% | 284.51% | 289.11% | 200.83% | 106.58% |
| Average Diluted Shares Outstanding | 138.41% | 284.51% | 289.11% | 200.83% | 106.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |